Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis

Overview of attention for article published in Journal of Neurology, July 2016

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news: 2 news outlets
policy: 1 policy source

twitter: 6 X users
facebook: 1 Facebook page

Citations

dimensions_citation: 191 Dimensions

Readers on

mendeley: 162 Mendeley

Summary News Policy documents X Facebook Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

Amicus: One Down, One To Go, More In The Lab

Seeking Alpha, 17 Feb 2019

Summary Amicus has one product, migalastat, recently approved for Fabry disease.

Morbus Pompe: Enzymersatz ist langfristig wirksam

Pharmazeutische Zeitung, 22 Feb 2017

Patienten mit der seltenen Glykogen-Speicherkrankheit Morbus Pompe profitieren auch langfristig von einer Enzymersatztherapie (EE…